48 related articles for article (PubMed ID: 10579803)
1. In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: behavioral and cellular responses after acute and chronic treatments.
Rubino T; Viganò D; Zagato E; Sala M; Parolaro D
Synapse; 2000 Jan; 35(1):8-14. PubMed ID: 10579803
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression.
Rubino T; Patrini G; Massi P; Fuzio D; Viganò D; Giagnoni G; Parolaro D
J Pharmacol Exp Ther; 1998 May; 285(2):813-9. PubMed ID: 9580631
[TBL] [Abstract][Full Text] [Related]
3. Changes in the cannabinoid receptor binding, G protein coupling, and cyclic AMP cascade in the CNS of rats tolerant to and dependent on the synthetic cannabinoid compound CP55,940.
Rubino T; Viganò D; Massi P; Parolaro D
J Neurochem; 2000 Nov; 75(5):2080-6. PubMed ID: 11032897
[TBL] [Abstract][Full Text] [Related]
4. Functional consequences of the acute administration of the cannabinoid receptor antagonist, SR141716A, in cannabinoid-naive and -tolerant animals: a quantitative 2-[14C]deoxyglucose study.
Freedland CS; Whitlow CT; Smith HR; Porrino LJ
Brain Res; 2003 Feb; 962(1-2):169-79. PubMed ID: 12543468
[TBL] [Abstract][Full Text] [Related]
5. SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonists.
Costa B; Colleoni M
Zhongguo Yao Li Xue Bao; 1999 Dec; 20(12):1103-8. PubMed ID: 11189200
[TBL] [Abstract][Full Text] [Related]
6. Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice.
Anggadiredja K; Yamaguchi T; Tanaka H; Shoyama Y; Watanabe S; Yamamoto T
Brain Res; 2003 Mar; 966(1):47-53. PubMed ID: 12646307
[TBL] [Abstract][Full Text] [Related]
7. Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral Delta9-tetrahydrocannabinol in rats.
Rubino T; Sala M; Viganò D; Braida D; Castiglioni C; Limonta V; Guidali C; Realini N; Parolaro D
Neuropsychopharmacology; 2007 Sep; 32(9):2036-45. PubMed ID: 17287821
[TBL] [Abstract][Full Text] [Related]
8. Precipitated and spontaneous withdrawal in rats tolerant to anandamide.
Costa B; Giagnoni G; Colleoni M
Psychopharmacology (Berl); 2000 Apr; 149(2):121-8. PubMed ID: 10805606
[TBL] [Abstract][Full Text] [Related]
9. Cannabinoid withdrawal is dependent upon PKA activation in the cerebellum.
Tzavara ET; Valjent E; Firmo C; Mas M; Beslot F; Defer N; Roques BP; Hanoune J; Maldonado R
Eur J Neurosci; 2000 Mar; 12(3):1038-46. PubMed ID: 10762335
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment with SR141716A, the CB1 receptor antagonist, influences morphine withdrawal syndrome.
Rubino T; Massi P; Viganò D; Fuzio D; Parolaro D
Life Sci; 2000 Apr; 66(22):2213-9. PubMed ID: 10834304
[TBL] [Abstract][Full Text] [Related]
11. Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions.
Rubino T; Vigano' D; Massi P; Spinello M; Zagato E; Giagnoni G; Parolaro D
Neuropharmacology; 2000 Apr; 39(7):1331-6. PubMed ID: 10760375
[TBL] [Abstract][Full Text] [Related]
12. In vivo characterization of a specific cannabinoid receptor antagonist (SR141716A): inhibition of delta 9-tetrahydrocannabinol-induced responses and apparent agonist activity.
Compton DR; Aceto MD; Lowe J; Martin BR
J Pharmacol Exp Ther; 1996 May; 277(2):586-94. PubMed ID: 8627535
[TBL] [Abstract][Full Text] [Related]
13. Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic ethanol administration.
Lallemand F; Soubrié PH; De Witte PH
Alcohol Clin Exp Res; 2001 Sep; 25(9):1317-23. PubMed ID: 11584151
[TBL] [Abstract][Full Text] [Related]
14. The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat.
Chapman V
Br J Pharmacol; 1999 Aug; 127(8):1765-7. PubMed ID: 10482905
[TBL] [Abstract][Full Text] [Related]
15. Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic alcohol administration combined with repeated re-exposures and withdrawals.
Lallemand F; Soubrié P; De Witte P
Alcohol Alcohol; 2004; 39(6):486-92. PubMed ID: 15466898
[TBL] [Abstract][Full Text] [Related]
16. Cannabinoid receptor antagonist SR141716A decreases operant ethanol self administration in rats exposed to ethanol-vapor chambers.
Rodríguez de Fonseca F; Roberts AJ; Bilbao A; Koob GF; Navarro M
Zhongguo Yao Li Xue Bao; 1999 Dec; 20(12):1109-14. PubMed ID: 11189201
[TBL] [Abstract][Full Text] [Related]
17. CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol.
Cook SA; Lowe JA; Martin BR
J Pharmacol Exp Ther; 1998 Jun; 285(3):1150-6. PubMed ID: 9618417
[TBL] [Abstract][Full Text] [Related]
18. Effects of SR141716A on ethanol and sucrose self-administration.
Freedland CS; Sharpe AL; Samson HH; Porrino LJ
Alcohol Clin Exp Res; 2001 Feb; 25(2):277-82. PubMed ID: 11236843
[TBL] [Abstract][Full Text] [Related]
19. 'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze.
Rodgers RJ; Haller J; Halasz J; Mikics E
Eur J Neurosci; 2003 Mar; 17(6):1279-86. PubMed ID: 12670316
[TBL] [Abstract][Full Text] [Related]
20. The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.
Tzavara ET; Davis RJ; Perry KW; Li X; Salhoff C; Bymaster FP; Witkin JM; Nomikos GG
Br J Pharmacol; 2003 Feb; 138(4):544-53. PubMed ID: 12598408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
